BioXcel Therapeutics, Inc.
BTAI · OTC
Share price · BTAI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BTAI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Sep 2026-37.1%
Nothing announced by BTAI that day or the session before.
- 28 Aug 2026-74.8%
- 17 Aug 2026-25.2%
Nothing announced by BTAI that day or the session before.
- 12 Aug 2026+13.7%
- Day beforeEntry into a material agreement
- 14 Jul 2026+16.8%
Nothing announced by BTAI that day or the session before.
- 8 Jul 2026-22.9%
Nothing announced by BTAI that day or the session before.
- 6 Jul 2026-20.3%
- 30 Apr 2026+18.3%
Nothing announced by BTAI that day or the session before.
- 1 Apr 2026-9.0%
Nothing announced by BTAI that day or the session before.
- 17 Mar 2026+12.3%
Nothing announced by BTAI that day or the session before.
Share of unusual movement by asset
For each asset, the share of BTAI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Dexmedetomidine (Igalmi) (Igalmi)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 14% |
| Sessions with no dated event | — | 86% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Alpha-2 adrenergic receptor (agonist)Small molecule | SchizophreniaBipolar DisorderAlzheimer's Disease Alzheimer's Disease Agitation |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.2M | $3.2M | $14M | $15M-$6.1M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0.2M | $3.0M | $17M | $13M-$12M operating cash flow | report ↗ |
| 2025-Q3 | $0.1M | $8.7M | $37M | $31M-$19M operating cash flow | report ↗ |
| 2025-Q2 | $0.1M | $10M | $19M | $19M-$13M operating cash flow | report ↗ |
| 2025-Q1 | $0.2M | $4.5M | $31M | $7.3M-$12M operating cash flow | report ↗ |
| 2024-Q3 | $0.2M | $5.1M | $40M | $14M-$16M operating cash flow | report ↗ |
| 2024-Q2 | $1.1M | $8.0M | $56M | $8.3M-$23M operating cash flow | report ↗ |
| 2024-Q1 | $0.6M | $11M | $74M | $27M-$18M operating cash flow | report ↗ |
| 2023-Q3 | $0.3M | $20M | $90M | $50M-$38M operating cash flow | report ↗ |
| 2023-Q2 | $0.5M | $27M | $128M | $54M-$38M operating cash flow | report ↗ |
| 2023-Q1 | $0.2M | $28M | $166M | $53M-$52M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $22M | $232M | $42M-$31M operating cash flow | report ↗ |
| 2022-Q2 | — | $18M | $233M | $38M-$33M operating cash flow | report ↗ |
| 2022-Q1 | — | $19M | $200M | $31M-$32M operating cash flow | report ↗ |
| 2021-Q3 | — | $12M | $253M | $27M-$20M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.6M | $30M | $29M | $17M-$58M operating cash flow | report ↗ |
BioXcel Therapeutics reported full-year 2025 revenue of $0.64M, down 71.8% YoY, with R&D spend of $30.25M, down 0.6% YoY. Cash and equivalents totaled $28.76M, and the company reported a net loss of $69.9M.
During the period, the company submitted an sNDA to the FDA seeking approval of IGALMI in the at-home setting for acute agitation associated with bipolar disorders or schizophrenia, with potential approval as early as year-end 2026, and advanced commercial preparations based on a third-party market assessment. It also continued the TRANQUILITY In-Care Phase 3 program for agitation associated with Alzheimer’s dementia, receiving FDA feedback and selecting a CRO for trial initiation, and reported positive Phase 2 topline results from a Columbia University-led investigator-sponsored trial of BXCL501 for opioid withdrawal.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($43K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-12 | Atkins Susan E. · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-06-15 | Mehta Vimal · director, CEO and President | Option exercise | 219 | — | — | Form 4 |
| 2026-06-15 | Yocca Frank · Chief Scientific Officer | Option exercise | 35 | — | — | Form 4 |
| 2026-06-15 | Steinhart Richard I · Chief Financial Officer | Option exercise | 35 | — | — | Form 4 |
| 2026-06-15 | Rodriguez Javier · See Remarks | Option exercise | 35 | — | — | Form 4 |
| 2026-06-15 | Mehta Vimal · director, CEO and President | Option exercise (derivative) | 219 | — | — | Form 4 |
| 2026-06-15 | Yocca Frank · Chief Scientific Officer | Option exercise (derivative) | 35 | — | — | Form 4 |
| 2026-06-15 | Steinhart Richard I · Chief Financial Officer | Option exercise (derivative) | 35 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 39 reporting institutions held 5.4M shares ($7.3M, 17.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MILLENNIUM MANAGEMENT LLC | 1,936,760 | $2.6M |
| 2 | ARMISTICE CAPITAL, LLC | 1,910,076 | $2.6M |
| 3 | OAKTREE CAPITAL MANAGEMENT LP | 241,188 | $323K |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 230,168 | $309K |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 207,339 | $278K |
| 6 | JONES FINANCIAL COMPANIES LLLP | 131,789 | $166K |
| 7 | Man Group plc | 96,473 | $129K |
| 8 | STATE STREET CORP | 92,118 | $123K |
| 9 | FMR LLC | 90,300 | $121K |
| 10 | VANGUARD FIDUCIARY TRUST CO | 84,921 | $114K |
| 11 | BlackRock, Inc. | 84,282 | $113K |
| 12 | &PARTNERS | 80,864 | $108K |
| 13 | UBS Group AG | 52,788 | $71K |
| 14 | Oaktree Fund Advisors, LLC | 42,913 | $58K |
| 15 | HighTower Advisors, LLC | 41,000 | $55K |